Skip to main content
Home
  • Solutions
    Clinical solutions
    Blended Solutions Cardiac Safety Solutions Clinical & Scientific Operations Decentralised Clinical Trials Early Clinical Laboratories Medical Imaging Site & Patient Solutions Strategic Solutions
    Consulting & Commercial
    Asset Development Consulting Commercial Positioning Language Services Outcome Measures Real World Intelligence Regulatory Affairs Symphony Health data
    meeting
    Case studies

    Reducing time to market, delivering on quality, providing deep therapeutic expertise and enhancing R&D ROI.

    Innovative research tools showcase
    Technologies

    Technology solutions from early phase through to post-marketing.

  • Sectors
    Sectors

    ICON provides its full range of clinical, consulting and commercial services across several industry sectors.

    Read more
    Biotech Government and Public Health Medical Device Pharmaceuticals
    Biotechnology services navigation panel
    Biotech

    Developing transformative therapies requires a flexible approach.

    Employee engagement program overview
    ICON and You

    Partners making a difference.

  • Therapeutics
    Therapeutics
    Cardiovascular Central Nervous System Endocrine & Metabolic Disorders Hepatology Infectious Diseases Internal Medicine & Immunology Oncology
    Cross-therapeutics
    Biosimilars Cell and Gene Therapies Medical Device Pediatrics Rare & Orphan Diseases Vaccines Women's Health
    Oncology whitepaper web assets
    Oncology

    An early pioneer in oncology CGT, ICON has contributed to over 60 FDA/EMA approved therapies in the last 5 years.

    Biological research visual element
    Therapeutics insights

    ICON's therapeutic experts contribute regularly to industry publications on the latest medical, scientific and clinical developments.

  • Insights
    Insights
    Digital Disruption Patient Centricity Regulatory Intelligence Therapeutics insights Transforming Trials Value Based Healthcare Blog Videos Webinar Channel
    whitepaper
    From innovation to implementation: Navigating neurologic monoclonal antibody development

    Strategies for clinical readiness on day one

    thumbnail
    Making sense of the rapidly changing biosimilars landscape

    Strategies for adapting and achieving optimal market access

    thumbnail
    Building a comparative evidence base using network meta-analysis

    Methods, implementation and reporting

  • News & Events
    News & Events

    ICON regularly contributes thought leadership to industry media publications and conferences, and has been recognised as one of the world’s leading Contract Research Organisations through a number of high-profile industry awards.

    Read more
    Press releases In the News Mediakit Awards Events Webinars Social media hub
    oligonucleotides
    Insights into first-in-human study design of oligonucleotides

    27 May 2026. Register now.

    Oncology whitepaper web assets
    ASCO 2026

    29 May - 2 June 2026, Booth #35093

  • About ICON
    About ICON
    Company history ICON at a glance ICON in Asia Pacific ICON in Latin America Leadership Quality
    ICON for
    Patients Healthy participants Investigators Jobs & Careers Investors Suppliers
    Responsible business practice indicators
    Sustainability, charity, inclusion and belonging

    ICON Cares is our commitment to making a positive impact on our people, environment and our community.

    Modern reception area at Dublin office
    ICON at a glance

    Delivering successful outcomes across the clinical development lifecycle.

  • Careers
  • Investors
  • Contact
  • 日本語
  • 简体中文
  1. Home
  2. News & Events
  3. Social media hub

Social media hub

Page tools
Share Share
Facebook

Share on Facebook

Facebook

Share on X

Facebook

Share on Linkedin

Bluesky

Share on Bluesky

ICON Plc facebook post
ICON Plc logo
ICON Plc

After a slow start, Project #Optimus is gaining traction among #biotechs. On the latest BioCentury Inc.: This Week podcast, ICON’s Dr Liz O’Brien, Senior Director, Drug Development Solutions, shares expert insights on ho...

29 Aug
5
View post
View webpage
ICON Plc facebook post
ICON Plc logo
ICON Plc

The specific needs of oncology clinical trials, alongside the distinct clinical pathway for biosimilars, mean that developing these treatments must be approached very differently from novel biologic development. To under...

29 Aug
4
View post
View webpage
ICON Plc facebook post
ICON Plc logo
ICON Plc

In recognition of National Immunisation Month, ICON experts analyse modern vaccine technologies. Learn about nucleic acid-based vaccine technologies, and vaccine delivery systems including viral vectors, virus-like par...

29 Aug
1
View post
View webpage
ICON Plc facebook post
ICON Plc logo
ICON Plc

Latest issue out now. If you, like our thousands of subscribers, would like a convenient way to keep on top of the latest regulatory authority updates, sign up to our free newsletter today. Compiled and collated by ICON...

29 Aug
2
View post
View webpage
ICON Plc facebook post
ICON Plc logo
ICON Plc

A proactive approach to vaccine long-term follow-up planning enhances data quality and supports evolving regulatory and public expectations for robust safety and effectiveness evidence. ICON’s Dinah Knotts and Ted Wright...

29 Aug
3
View post
View webpage
ICON Plc facebook post
ICON Plc logo
ICON Plc

Obesity trials are evolving, and weight alone is no longer enough. Join our live webinar to explore how the complementary tools of COAs + DHTs can deliver richer patient insights, enhancing obesity clinical trials. 📅 O...

28 Aug
4
View post
View webpage
ICON Plc facebook post
ICON Plc logo
ICON Plc

Transforming partnerships through flexibility and focus. ​ Discover how ICON helped a sponsor transition to a blended model—combining FSO, FSP and standalone services for greater control and efficiency. https://ow.ly/y3...

28 Aug
2
View post
View webpage
ICON Plc facebook post
ICON Plc logo
ICON Plc

Antibody-Drug Conjugates (ADCs) combine potent cytotoxins with selective antibodies for targeted cancer therapy—but their complexity presents major challenges in pharmacokinetics (PK) and bioanalysis. In our latest artic...

28 Aug
4
View post
View webpage
ICON Plc facebook post
ICON Plc logo
ICON Plc

ICON is delighted to continue its partnership with the Outsourcing in Clinical Trials Southern California conference taking place 23 – 24 September at the Hyatt Regency La Jolla at Aventine, San Diego, CA. Join us at b...

27 Aug
4
View post
View webpage
ICON Plc facebook post
ICON Plc logo
ICON Plc

ICON will be on site at #DPHARM2025, 16–17 September at the Loews Philadelphia Hotel, where the focus is on transforming clinical research through disruptive innovation. Meet our team at booth #305 to discuss how ICON’s ...

27 Aug
5
View post
View webpage
ICON Plc facebook post
ICON Plc logo
ICON Plc

The volume of life sciences research is growing fast - making it harder than ever to find reliable insights. Our new whitepaper shows you how to use systematic literature reviews (SLRs) to generate high-quality evidence ...

26 Aug
3
View post
View webpage
ICON Plc facebook post
ICON Plc logo
ICON Plc

Agencies like the FDA and EMA are more receptive to submissions integrating evidence across indications, lowering barriers for label expansion. But what commercialisation strategies are most successful following regul...

26 Aug
View post
View webpage
  • Previous
  • 1
  • …
  • 102
  • 103
  • 104
  • …
  • 106
  • Next
Filter by:

Filter by:

Site Branding
    ICON plc
  • Contact
  • About ICON
  • Results & Reports
For Clients
  • Therapeutics
  • Solutions
  • Insights
  • Technologies
  • Office locations
ICON for
  • Patients
  • Volunteers
  • Investigators
  • Jobs & Careers
  • Investors
  • Suppliers
News & Events
  • Press releases
  • Mediakit
  • Events
  • Webinars
  • Social media hub
Socials
  • Linkedin
  • Facebook
  • Instagram
  • Youtube

Legal Footer

  • © 2026 ICON plc
  • Disclaimer
  • Privacy & Data
  • Cookies